AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29773527 — intervention group
Group type: COMPARATOR
Intervention: No SMS
Number of subjects: 63
Study 29773572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathogen-inactivated platelets (using riboflavin and UV B illumination technology)
Number of subjects: 469
Study 29773572 — intervention group
Group type: COMPARATOR
Intervention: Standard plasma-stored platelets
Number of subjects: 469
Study 29773593 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 284
Study 29773601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial targeting of XPO1 and FLT3
Number of subjects: 0
Study 29773661 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncolytic Vaccinia Virus GL-ONC1
Number of subjects: 0
Study 29773698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based formula (AAF) for 2 weeks followed by an open food challenge (OFC) with standard cow's milk formula and a home challenge for another 2 weeks.
Number of subjects: 0
Study 29773698 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CoMiSS score before AAF treatment.
Number of subjects: 0
Study 29773699 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfer group (FET performed in the first cycle following stimulated IVF)
Number of subjects: 724
Study 29773699 — intervention group
Group type: COMPARATOR
Intervention: Delayed transfer group (FET performed at least in the second cycle following stimulated IVF)
Number of subjects: 724
Study 29773949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAT)
Number of subjects: 3420
Study 29773969 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 mcg
Number of subjects: 0
Study 29774030 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-470 vaccine
Number of subjects: 0
Study 29774030 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose IFNα2b
Number of subjects: 0
Study 29774051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study 29774169 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.
Number of subjects: 57
Study 29774169 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily
Number of subjects: 57
Study 29775078 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental Reciprocity Treatment
Number of subjects: 22
Study 29775807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg on day 1 (21-day cycles)
Number of subjects: 138
Study 29776017 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04236921 (anti-interleukin-6 monoclonal antibody)
Number of subjects: 0
Study 29776017 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04236921
Number of subjects: 0
Study 29776373 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg intravenously, weekly pegylated recombinant arginase (BCT-100)
Number of subjects: 1
Study 29776373 — intervention group
Group type: COMPARATOR
Intervention: Control samples (not specified)
Number of subjects: 1
Study 29776382 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiostereometric Analysis (RSA)
Number of subjects: 7
Study 29776382 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom study with RSA
Number of subjects: 7
Study 29776789 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cTBS (110% resting motor threshold, 3600 pulses, Fp1 location)
Number of subjects: 49
Study 29776789 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS
Number of subjects: 49
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive breast cancer
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node involvement
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal income <€1900/month
Number of subjects: 178
Study 29776920 — intervention group
Group type: EXPERIMENTAL
Intervention: Not receiving the patient information booklet on RTW
Number of subjects: 178
Study 29777016 — intervention group
Group type: EXPERIMENTAL
Intervention: e-ASPECTS scores (automated system for quantifying signs of infarction)
Number of subjects: 1480
Study 29777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 29777230 — intervention group
Group type: COMPARATOR
Intervention: Baseline CRP levels
Number of subjects: 0
Study 29777230 — intervention group
Group type: COMPARATOR
Intervention: Baseline CC levels
Number of subjects: 0
Study 29777230 — intervention group
Group type: COMPARATOR
Intervention: Baseline leptin levels
Number of subjects: 0
Study 29777230 — intervention group
Group type: COMPARATOR
Intervention: Baseline ghrelin levels
Number of subjects: 0
Study 29777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 29777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in leptin levels
Number of subjects: 0
Study 29777230 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in CC levels
Number of subjects: 0
Study 29777235 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% caloric restriction for 6 weeks
Number of subjects: 12
Study 29777235 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle UCP2 expression changes
Number of subjects: 12
Study 29777235 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression changes in skeletal muscle and adipose tissue
Number of subjects: 12
Study 29777235 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered catecholamine and FGF21 concentrations
Number of subjects: 12
Study 29777299 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 1
Study 29777299 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1
Study 29777373 — intervention group
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF™ system
Number of subjects: 230
Study 29777402 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic systemic imaging during follow-up
Number of subjects: 10838
Study 29777402 — intervention group
Group type: EXPERIMENTAL
Intervention: First follow-up year imaging
Number of subjects: 10838
Study 29777402 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen receptor/progesterone receptor-negative tumors
Number of subjects: 10838
Study 29777631 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox + erythropoietin
Number of subjects: 23
Study 29777631 — intervention group
Group type: COMPARATOR
Intervention: Erythropoietin alone
Number of subjects: 23
Study 29777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep bruxism assessment through questionnaires, clinical symptoms, and electromyographic/electrocardiographic data.
Number of subjects: 0
Study 29777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic stress assessment.
Number of subjects: 0
Study 29777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep quality assessment.
Number of subjects: 0
Study 29777735 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep bruxism presence.
Number of subjects: 0
Study 29777825 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) recordings from participants exposed to different exemplar images of the same object concepts.
Number of subjects: 32
Study 29777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 0
Study 29777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimuscarinics
Number of subjects: 0
Study 29777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching therapy
Number of subjects: 0
Study 29778365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds
Number of subjects: 1490
Study 29778365 — intervention group
Group type: COMPARATOR
Intervention: No cerebral microbleeds
Number of subjects: 1490
Study 29778365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds and HAS-BLED score
Number of subjects: 1490
Study 29778365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds, diabetes, anticoagulant type, and HAS-BLED
Number of subjects: 1490
Study 29778365 — intervention group
Group type: COMPARATOR
Intervention: HAS-BLED score alone
Number of subjects: 1490
Study 29778515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional intradermal vaccination with quadrivalent conjugate vaccine (MenACWY-CRM)
Number of subjects: 12
Study 29778515 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid conjugated vaccine (Nimenrix®)
Number of subjects: 12
Study 29778738 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (methotrexate, vincristine, cisplatin, and cyclophosphamide) with high-risk patients receiving additional vinblastine.
Number of subjects: 81
Study 29779023 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CKD
Number of subjects: 58
Study 29779023 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 58
Study 29779023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups analyzed together
Number of subjects: 58
Study 29779054 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of fruits and vegetables and whole-grain products
Number of subjects: 922
Study 29779054 — intervention group
Group type: COMPARATOR
Intervention: Lipid accumulation product
Number of subjects: 922
Study 29779129 — intervention group
Group type: EXPERIMENTAL
Intervention: AFM-guided patients
Number of subjects: 84
Study 29779129 — intervention group
Group type: COMPARATOR
Intervention: Control group (manual GDFT strategy)
Number of subjects: 84
Study 29779774 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated NALC/NaOH-decontamination
Number of subjects: 0
Study 29779774 — intervention group
Group type: COMPARATOR
Intervention: Control (single NALC/NaOH-decontamination)
Number of subjects: 0
Study 29779835 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Number of subjects: 23
Study 29780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated antigen-typing algorithm based on whole-genome sequencing (bloodTyper)
Number of subjects: 200
Study 29780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved bloodTyper algorithm
Number of subjects: 200
Study 29780001 — intervention group
Group type: EXPERIMENTAL
Intervention: Final bloodTyper algorithm
Number of subjects: 200
Study 29780029 — intervention group
Group type: EXPERIMENTAL
Intervention: ABLE programme
Number of subjects: 30
Study 29780263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 1184
Study 29780263 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 1184
Study 29780318 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming intervention for 6 months
Number of subjects: 0
Study 29780318 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 0
Study 29780414 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis with trimethoprim-sulfamethoxazole
Number of subjects: 70
Study 29780414 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic treatment
Number of subjects: 70
Study 29780848 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human hookworm infection (CHHI)
Number of subjects: 0
Study 29780848 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 29780852 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (amantadine) extended release capsules, 274 mg once daily at bedtime for up to two years
Number of subjects: 0
Study 29780852 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in previous randomized controlled trial)
Number of subjects: 0
Study 29781056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat with docetaxel (arm 1, n=22)
Number of subjects: 64
Study 29781056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat with carboplatin plus paclitaxel (arm 2, n=26)
Number of subjects: 64
Study 29781056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat with gemcitabine (arm 3, n=10)
Number of subjects: 64
Study 29781056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in cohort for carboplatin dose (arm 2a, n=6)
Number of subjects: 64
Study 29781237 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (Dysport®)
Number of subjects: 0
Study 29781237 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRC model
Number of subjects: 0
Study 29781237 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Model Repeated Measures analyses
Number of subjects: 0
Study 29781237 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 29781568 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic dysfunction (DD)
Number of subjects: 20
Study 29781568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to prevent or delay DD
Number of subjects: 20
Study 29781833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, sex, employment, profession, marital status)
Number of subjects: 3227
Study 29781833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors (age, sex, employment, marital status)
Number of subjects: 3227
Study 29781974 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape-descriptive factors
Number of subjects: 201
Study 29782179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 367
Study 29782179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 367
Study 29782642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (q12h) until month 3, then adjusted to either 5 or 10 mg q12h.
Number of subjects: 2867
Study 29782824 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE-ε4 carriers
Number of subjects: 298
Study 29782824 — intervention group
Group type: COMPARATOR
Intervention: Non-APOE-ε4 carriers
Number of subjects: 298
Study 29783928 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (4 sessions of supervised physical activity and a home-based exercise program)
Number of subjects: 226
Study 29783928 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 226
Study 29784042 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant oxaliplatin and capecitabine (XELOX) combined with bevacizumab plus radiotherapy
Number of subjects: 45
Study 29784059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) using a low-energy diet (LED) meal replacement approach combined with physical activity
Number of subjects: 138
Study 29784059 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 138
Study 29784059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 138
Study 29784469 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose (27,476 IU)
Number of subjects: 318
Study 29784469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered doses (10,447 IU, 3013 IU, 587 IU)
Number of subjects: 318
Study 29784469 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered doses (158 IU, 31 IU)
Number of subjects: 318
Study 29784633 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy
Number of subjects: 14
Study 29784633 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 14
Study 29784633 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy and optical coherence tomography
Number of subjects: 14
Study 29784635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary app and additional health counseling by telephone calls from a diabetes specialist nurse (n=50)
Number of subjects: 101
Study 29784635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone with diabetes diary app (n=51)
Number of subjects: 101
Study 29784635 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study 29784747 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for uveal melanoma based on tumor size
Number of subjects: 0
Study 29784747 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with immunotherapies for cutaneous melanoma
Number of subjects: 0
Study 29784747 — intervention group
Group type: COMPARATOR
Intervention: Second-line treatment in metastatic melanoma
Number of subjects: 0
Study 29785141 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening method for cardiovascular risk assessment
Number of subjects: 0
Study 29785141 — intervention group
Group type: COMPARATOR
Intervention: Standard screening method for cardiovascular risk assessment
Number of subjects: 0
Study 29785275 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal knowledge about correct infant sleep position (back)
Number of subjects: 54
Study 29785275 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance with expert recommendations for infant sleep
Number of subjects: 54
Study 29785275 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of meeting sleep duration recommendations
Number of subjects: 54
Study 29785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0 mg every 4 weeks (2q4)
Number of subjects: 862
Study 29785301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8)
Number of subjects: 862
Study 29785301 — intervention group
Group type: COMPARATOR
Intervention: Laser control treatment
Number of subjects: 862
Study 29785458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution standardized laparoscopic cholecystectomy protocol (HRSL)
Number of subjects: 39
Study 29785458 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention)
Number of subjects: 39
Study 29785458 — intervention group
Group type: COMPARATOR
Intervention: Control group (post-intervention)
Number of subjects: 39
Study 29785473 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous melatonin levels preoperatively compared to intraoperative and postoperative levels
Number of subjects: 30
Study 29785473 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma melatonin levels correlation with postoperative morphine consumption
Number of subjects: 30
Study 29785473 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cortisol levels compared to intraoperative and postoperative levels
Number of subjects: 30
Study 29785473 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperatures across all measurement periods
Number of subjects: 30
Study 29785473 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in endogenous melatonin levels and morphine consumption
Number of subjects: 30
Study 29785539 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg single dose
Number of subjects: 400
Study 29785539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 29785709 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib with rituximab (IR)
Number of subjects: 50
Study 29786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients cared by family/proxies or community nurses
Number of subjects: 26853
Study 29786762 — intervention group
Group type: COMPARATOR
Intervention: Patients living in homes
Number of subjects: 26853
Study 29786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients over 80 years of age
Number of subjects: 26853
Study 29786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients over 90 years of age
Number of subjects: 26853
Study 29786762 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 26853
Study 29787575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (IV tPA)
Number of subjects: 20
Study 29787734 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) including specific diaphragm techniques
Number of subjects: 66
Study 29787734 — intervention group
Group type: COMPARATOR
Intervention: Sham diaphragm intervention
Number of subjects: 66
Study 29788155 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0575 and gemcitabine (1000 mg/m2 or 500 mg/m2)
Number of subjects: 102
Study 29788155 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0575 monotherapy
Number of subjects: 102
Study 29788155 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0575 and gemcitabine
Number of subjects: 102
Study 29788339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold chain capacity of -60°C or colder for the STRIVE Ebola vaccine trial
Number of subjects: 0
Study 29788340 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilizing nurses to staff the clinical trial for the Ebola vaccine.
Number of subjects: 0
Study 29788341 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIVE intervention during the Ebola outbreak
Number of subjects: 0
Study 29788342 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0
Study 29788342 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29788343 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with rVSV∆G-ZEBOV-GP vaccine (within 7 days)
Number of subjects: 8600
Study 29788343 — intervention group
Group type: COMPARATOR
Intervention: Deferred vaccination (within 18-24 weeks)
Number of subjects: 8600
Study 29788345 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP Vaccine
Number of subjects: 0
Study 29788345 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29788346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine
Number of subjects: 0
Study 29788346 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29788347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine intervention
Number of subjects: 0
Study 29788347 — intervention group
Group type: COMPARATOR
Intervention: Control group (if applicable)
Number of subjects: 0
Study 29788348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0